CRISPR-Based Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Product, Application, End-use, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
CRISPR-Based Diagnostics Market size was valued at USD 4.04 billion in 2026 and is anticipated to grow at a 17.26% CAGR from 2027 to 2036, crossing USD 19.86 billion by 2036. The industry revenue for 2027 is calculated at USD 4.64 billion.
Get more details on this report
Request Free Sample ReportCRISPR-Based Diagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America leads through advanced biotechnology infrastructure, strong research activity, and growing molecular diagnostics adoption, creating favorable conditions for innovation and commercialization.
- Asia Pacific is expected to grow fastest as healthcare infrastructure expands, biotechnology investments increase, and demand for rapid molecular testing strengthens across infectious disease and precision medicine applications.
Segment Momentum
- Kits and reagents accounted for 59.26% of the market in 2026, supported by their essential role in consistent diagnostic workflows. Ready-to-use components and simplified testing formats help laboratories implement molecular detection efficiently.
- Infectious disease diagnostics held 54.48% of the market in 2026 and are also expected to grow fastest, driven by demand for rapid pathogen detection, adaptable assays, and decentralized testing for timely diagnostic decisions.
Market Expansion Drivers
- Adoption of CRISPR-based Diagnostic Tools.
- Expansion of Molecular Diagnostics in Healthcare.
- Technological Advancements in Gene Editing & Detection.
Leading Market Participants
- Prominent players in the CRISPR-based diagnostics market include Mammoth Biosciences (USA), Sherlock Biosciences (USA), Synthego (USA), CasZyme (USA), BioXpedia (UK), CRISPR Therapeutics (Switzerland), Caribou Biosciences (USA), Integrated DNA Technologies (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 4.04 billion
- 2027 Estimated Market Size: USD 4.64 billion
- Projected Market Size: USD 19.86 billion by 2036
- Growth Forecast: 17.26% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Product (Kits and Reagents) | Application (Infectious Disease Diagnostics) | End-use (Laboratories) | Technology (Cas12)
- Emerging Opportunity Segment: Product (Kits and Reagents) | Application (Infectious Disease Diagnostics) | End-use (Laboratories) | Technology (Cas12)
Market Growth Drivers and Industry Trends
Adoption of CRISPR-based Diagnostic Tools
Growing adoption of CRISPR-based diagnostic tools is driven by their ability to identify specific genetic sequences with high selectivity and enable rapid detection of biological targets. The programmability of CRISPR systems allows diagnostic platforms to be adapted for different pathogens, genetic conditions, and molecular biomarkers, creating opportunities for use across clinical and decentralized testing environments. As healthcare systems increasingly seek faster and more targeted diagnostic approaches, the versatility of CRISPR-based detection is supporting its integration into emerging molecular testing workflows.
Expansion of Molecular Diagnostics in Healthcare
The expanding role of molecular diagnostics in healthcare is increasing demand for technologies capable of detecting disease-associated genetic and molecular signatures with greater specificity. Molecular testing is becoming increasingly relevant across infectious disease detection, inherited disorders, oncology, and personalized healthcare, creating a broader application base for advanced diagnostic platforms. The need for rapid and accessible testing solutions, particularly where conventional diagnostic workflows may be time-consuming or resource-intensive, is encouraging interest in CRISPR-based approaches and supporting market development.
Technological Advancements in Gene Editing & Detection
Ongoing advancements in CRISPR gene-editing systems and molecular detection methods are improving the adaptability, sensitivity, and usability of CRISPR-based diagnostic platforms. Innovations in guide RNA design, signal amplification, multiplex detection, and portable assay formats are enabling researchers to develop diagnostic systems capable of addressing increasingly complex testing requirements. Greater integration of CRISPR mechanisms with streamlined detection technologies is also supporting the development of rapid and potentially decentralized testing solutions, expanding the technology's relevance across clinical, laboratory, and point-of-care applications.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Adoption of CRISPR-based Diagnostic Tools | 6% | Short term (≤ 2 yrs) | North America; Europe | High | Fast |
| Expansion of Molecular Diagnostics in Healthcare | 5.5% | Medium term (2–5 yrs) | Asia Pacific; North America | Medium | Moderate |
| Technological Advancements in Gene Editing & Detection | 5.7% | Long term (5+ yrs) | Europe; Asia Pacific | Low | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share in 2026, supported by advanced biotechnology infrastructure, strong research activity, and growing adoption of molecular diagnostic technologies. The region has a well-developed ecosystem for genetic research, infectious disease testing, and precision medicine, creating favorable conditions for the development and commercialization of CRISPR-based diagnostic platforms. CRISPR technologies can provide highly specific detection of genetic sequences and have potential applications across infectious diseases, cancer diagnostics, genetic disorders, and other molecular testing areas. Increasing demand for rapid and accurate diagnostic tools is encouraging research into CRISPR-enabled approaches that can complement conventional molecular testing methods. Strong collaboration among research institutions, healthcare organizations, and biotechnology developers is also supporting innovation in gene-editing-based diagnostics. As molecular testing becomes increasingly important for disease detection and personalized healthcare, demand for advanced CRISPR-based diagnostic technologies is expanding across North America.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to be the fastest-growing region, impelled by expanding healthcare infrastructure, rising demand for molecular diagnostics, and increasing research activity in genomics and biotechnology. The region faces substantial diagnostic needs across infectious diseases and other conditions, creating opportunities for rapid, sensitive, and potentially decentralized testing technologies. CRISPR-based diagnostics can support detection of specific genetic targets while offering potential advantages in speed and adaptability, making the technology attractive for applications beyond conventional laboratory settings. Growing investments in biotechnology research and the modernization of diagnostic laboratories are further supporting technology adoption. Increasing awareness of precision medicine and the broader integration of advanced genetic technologies into healthcare systems are also creating favorable market conditions. As research capabilities and access to molecular testing continue to expand, the adoption of CRISPR-based diagnostics is accelerating across Asia Pacific.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Translational Diagnostic InnovationThe U.S. is prioritizing translation of CRISPR-based diagnostic platforms from research into clinically useful testing, particularly where rapid and programmable detection can address infectious diseases and molecular targets. Commercial priorities include assay validation, regulatory pathways, scalable manufacturing, and integration with decentralized or point-of-care diagnostic workflows.
Germany 🇩🇪
Clinical Validation FocusGermany’s CRISPR-based diagnostics market is shaped by strong interest in clinically reliable molecular testing and laboratory innovation. Developers are likely to emphasize analytical validation, reproducible assay performance, regulatory readiness, and integration with established diagnostic infrastructure to move CRISPR-enabled detection toward practical clinical and laboratory applications.
Japan 🇯🇵
Precision Testing ApplicationsJapan is positioned toward applying CRISPR diagnostic technologies to precision molecular testing, where rapid target identification and assay specificity can complement established diagnostic methods. Market priorities include compact testing platforms, robust assay design, automation, and applications spanning infectious disease surveillance and specialized clinical diagnostics.
South Korea 🇰🇷
Platform CommercializationSouth Korea is emphasizing commercialization of advanced molecular diagnostic platforms, creating opportunities for CRISPR systems that combine rapid detection with adaptable target design. Key priorities include assay miniaturization, multiplexing, manufacturing scalability, and deployment across clinical laboratories and decentralized testing environments.
France 🇫🇷
Decentralized Testing DevelopmentFrance is exploring advanced molecular diagnostics that can improve the speed and accessibility of pathogen and biomarker detection. For CRISPR-based platforms, commercial priorities include point-of-care usability, reliable sample-to-answer workflows, clinical validation, and integration with healthcare testing networks.
Italy 🇮🇹
Specialized Diagnostic AdoptionItaly offers scope for CRISPR-based diagnostics in specialized molecular testing, particularly where conventional workflows can benefit from faster or more targeted detection. Market priorities include demonstrating clinical utility, strengthening laboratory adoption, and developing cost-conscious platforms suitable for infectious disease and precision diagnostic applications.
CRISPR-Based Diagnostics Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Kits and Reagents (Largest & Fastest-Growing Segment)
Kits and reagents accounted for the largest market share of 59.26% in 2026 and are also expected to register the fastest growth, driven by the central role of ready-to-use molecular components in enabling CRISPR-based diagnostic testing. Kits and reagents integrate the detection components, reaction materials, and other essential elements required to identify specific genetic or molecular targets, helping laboratories and diagnostic settings implement CRISPR-based workflows with greater consistency and efficiency. Their growing adoption is supported by the demand for rapid, sensitive, and programmable diagnostic technologies capable of addressing a broad range of targets. Advances in CRISPR detection mechanisms are also enabling the development of increasingly versatile diagnostic formats that can be adapted to different testing requirements. In addition, the growing emphasis on decentralized and point-of-care diagnostics is creating demand for simplified kits that can reduce workflow complexity and support faster testing. Continued innovation in reagent stability, assay design, multiplexing, and ease of use is expected to further strengthen the role of kits and reagents in the CRISPR-based diagnostics market.
Application Segment Analysis: Infectious Disease Diagnostics (Largest & Fastest-Growing Segment)
Infectious disease diagnostics accounted for the largest 2026 market share of 54.48% and are also expected to experience the fastest growth, supported by the need for rapid and accurate detection of infectious pathogens. CRISPR-based diagnostic technologies offer the ability to identify specific genetic sequences associated with pathogens, creating opportunities for sensitive testing across viral, bacterial, and other infectious diseases. The demand for faster diagnostic decision-making is particularly important when timely identification can support appropriate treatment, isolation, and disease-control measures. Growing awareness of emerging and re-emerging infectious threats is further encouraging the development of diagnostic technologies that can be rapidly adapted to new targets. In addition, the potential for CRISPR-based assays to support decentralized testing is expanding their relevance beyond conventional laboratory environments. Continued improvements in assay sensitivity, specificity, portability, and multiplex detection are strengthening the applicability of CRISPR diagnostics for infectious disease testing and supporting sustained market expansion.
End-use Segment Analysis: Laboratories (Largest & Fastest-Growing Segment)
Laboratories accounted for the largest share of 46.69% in 2026 and are also expected to capture a growing market share at the fastest pace, driven by the expanding use of advanced molecular diagnostic technologies for pathogen detection, genetic analysis, and research applications. Laboratories provide the infrastructure, technical expertise, and controlled testing environments required to implement CRISPR-based diagnostic workflows and validate emerging assays. The increasing demand for rapid molecular testing is encouraging laboratories to adopt technologies that can complement conventional diagnostic methods and provide targeted detection capabilities. CRISPR-based platforms are particularly relevant where laboratories require adaptable assays capable of identifying specific genetic sequences with high analytical precision. Furthermore, ongoing research into new CRISPR detection mechanisms and broader diagnostic applications is creating additional opportunities for laboratory adoption. Improvements in workflow automation, assay standardization, and integration with digital laboratory systems are also helping enhance operational efficiency, supporting the expanding role of laboratories in the development and use of CRISPR-based diagnostic technologies.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Enzymes, Kits and Reagents, Software and Libraries | Kits and Reagents | Kits and Reagents |
| Application | Infectious Disease Diagnostics, Genetic Disorder Diagnostics, Cancer Diagnostics, Others | Infectious Disease Diagnostics | Infectious Disease Diagnostics |
| End-use | Hospitals and Clinics Diagnostic, Laboratories, Pharmaceutical and Biotechnology Companies, Others | Laboratories | Laboratories |
| Technology | Cas9, Cas12, Others | Cas12 | Cas12 |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Fusing CRISPR mechanisms with isothermal amplification eliminates the reliance on bulky thermal cyclers, driving rapid decentralized testing while balancing sensitivity and workflow simplicity. At the same time, engineered Cas enzymes with enhanced PAM flexibility expand target sequence compatibility, broadening actionable diagnostic scopes. To successfully extend reach into point-of-care and direct-to-consumer multiplex settings, platforms must ensure straightforward result interpretation alongside robust multi-pathogen detection. Crucially, navigate-able patent licensing architectures and unencumbered commercialization rights dictate whether innovative platforms can scale efficiently past regulatory and market entry barriers.
Key companies in the CRISPR-based diagnostics market:
- Mammoth Biosciences (USA)
- Sherlock Biosciences (USA)
- Synthego (USA)
- CasZyme (USA)
- BioXpedia (UK)
- CRISPR Therapeutics (Switzerland)
- Caribou Biosciences (USA)
- Integrated DNA Technologies (USA)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Mammoth Biosciences (USA) | |||||||
| Sherlock Biosciences (USA) | |||||||
| Synthego (USA) | |||||||
| CasZyme (USA) | |||||||
| BioXpedia (UK) | |||||||
| CRISPR Therapeutics (Switzerland) | |||||||
| Caribou Biosciences (USA) | |||||||
| Integrated DNA Technologies (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| CrisprBits | November 2025 | CrisprBits raised USD 3 million in funding to scale its CRISPR platforms dedicated to diagnostics and gene editing. This financial infusion is directed toward expanding the company’s technology capabilities, thereby strengthening its capacity to develop and commercialize advanced applications across molecular diagnostics and gene-editing use cases. |
| VedaBio | September 2025 | VedaBio secured a non-exclusive license agreement with Mammoth Biosciences to integrate proprietary CRISPR technologies into its diagnostic solutions. This strategic collaboration expands VedaBio's molecular detection platform and provides crucial access to specialized CRISPR technology for advancing diagnostic applications. |
| IntelliGenome | January 2025 | IntelliGenome’s CRISPR-TB Blood Test was granted FDA Breakthrough Device Designation for identifying Mycobacterium tuberculosis cell-free DNA in blood samples. This regulatory milestone marks a significant validation for the company's novel CRISPR-based diagnostic approach targeted at tuberculosis detection. |
| CrisprBits | January 2025 | CrisprBits inaugurated its Research and Innovation Centre in Bengaluru, India, focusing on CRISPR gene editing and diagnostics. The new facility features advanced infrastructure, including specialized areas for lyophilization, cell and tissue culture, molecular biology research, and cleanroom operations. |
| Jumpcode Genomics | June 2024 | Jumpcode Genomics settled its patent dispute with Takara Bio USA and established a strategic partnership to combine intellectual property assets. The collaboration integrates CRISPR-based technology to enable the targeted removal of unwanted transcripts, such as ribosomal RNAs, from next-generation sequencing libraries. |
| Scope Biosciences | March 2024 | Scope Biosciences secured USD 2.68 million through the EIC Transition program to support molecular diagnostics innovation. The grant builds upon a prior collaboration with Wageningen University and aims to accelerate the commercial development of the scopeDx platform for high-accuracy point-of-care testing. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
CRISPR-Based Diagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood & Serum, Saliva & Oral Samples, Nasal & Respiratory Samples, Tissue & Biopsy Samples, Urine & Other Body Fluids |
| Test Format | Point-of-Care Tests, Laboratory-Based Tests, Cartridge-Based Tests, Microfluidic Tests |
| Testing Workflow | Manual Testing Workflows, Semi-Automated Workflows, Fully Automated Workflows |
CRISPR-Based Diagnostics Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Clinical Adoption Pathway Assessment |
|
| Regulatory Approval Strategy |
|
| Reimbursement & Market Access Outlook |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How big is the CRISPR-based diagnostics market?
What are the growth projections for the CRISPR-based diagnostics industry?
How is the expansion of molecular diagnostics creating new opportunities for CRISPR-based diagnostic platforms?
How are CRISPR detection advances influencing the deployment potential of diagnostic platforms?
Why do kits and reagents lead the CRISPR-based diagnostics market?
How is infectious disease testing driving demand for CRISPR-based diagnostics?
Why does North America lead the CRISPR-based diagnostics market?
Why is Asia Pacific becoming a key growth market for CRISPR-based diagnostics?
Who holds a significant market share in the CRISPR-based diagnostics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook